Page 233 - Haematologica Vol. 110 - January 2025
P. 233
LETTER TO THE EDITOR A
B
Figure 1. Outcomes of advanced systemic mastocytosis patients treated with midostaurin or cladribine according to CD2 ex- pression on mast cells. (A) Kaplan-Meier estimates of overall survival (OS) according to CD2 expression on bone marrow (BM) mast cells in midostaurin-treated patients with advanced systemic mastocytosis (Adv-SM). (B) Kaplan-Meier estimates of time to treatment failure (TTF) according to CD2 expression on BM mast cells in cladribine-treated patients with Adv-SM. OS and TTF since the start of treatment for each group were analyzed using the Kaplan-Meier estimator. Estimates of hazard functions were compared using the log rank test. CI: Confidence Interval; NA: not achieved.
Haematologica | 110 January 2025
225
